Circulating cell-free-DNA concentration is a good biomarker for diagnosis of colorectal cancer in Mexican patients

Saucedo-Sariñana, Anílu Margarita; Lugo-Escalante, Carlos Roberto; Barros‐Núñez, Patricio; Marín-Contreras, María Eugenia; Pineda-Razo, Tomás Daniel; Mariscal-Ramírez, Ignacio; Gallegos‐Arreola, Martha Patricia; Rosales-Reynoso, Mónica Alejandra

doi:10.14715/cmb/2022.68.6.1

Cited by 10 publications

(9 citation statements)

References 40 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In autoimmune disorders and infectious diseases, the concentration and composition of ccfDNA can act as markers of disease activity and progression, aiding in the assessment of disease severity and the prediction of disease trajectory. This broad applicability across various diseases highlights the potential of ccfDNA as a universal biomarker in clinical prognostics [36].…”

Section: Med Biomedical J2024 Volume [1] |Issue [1] | 28mentioning

confidence: 93%

Exploring the Role of Circulating Cell-Free DNA in Disease Diagnosis and Therapy

Odah

2024

Preprint

View full text Add to dashboard Cite

Recent advancements in molecular diagnostics have highlighted the potential of circulating cell-free DNA (ccfDNA) as a biomarker in various diseases. This study aims to explore the role of ccfDNA in the early diagnosis, prognosis, and therapeutic monitoring of diseases, with a focus on oncology. We conducted a comprehensive review and analysis of current literature, combined with experimental approaches involving advanced genomic sequencing and bioinformatics techniques. Our research systematically characterizes the molecular composition of ccfDNA, including its origins, size distribution, and methylation patterns, across different disease states. Furthermore, we investigate the dynamics of ccfDNA release and clearance in the bloodstream, elucidating mechanisms that could influence its diagnostic accuracy. In the context of cancer, we analyze the correlation between tumor-derived ccfDNA and disease progression, response to therapy, and overall survival. Our findings indicate that ccfDNA holds promise as a non-invasive biomarker for early disease detection, real-time monitoring of treatment efficacy, and potentially, predicting relapse. This study contributes to the growing field of liquid biopsies and opens new avenues for personalized medicine, emphasizing the need for standardized protocols in ccfDNA analysis to maximize its clinical utility. The implications of our findings extend beyond oncology, suggesting potential applications of ccfDNA in other pathological conditions.

show abstract

Section: Med Biomedical J2024 Volume [1] |Issue [1] | 28mentioning

confidence: 93%

Exploring the Role of Circulating Cell-Free DNA in Disease Diagnosis and Therapy

Odah

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The concentration of cfDNA was measured using a Quant-iT dsDNA Assay Kit (Thermo Scientific). To quantify the cfDNA yield, a fragment of 247 and 115 bp of the Alu gene sequence was amplified with a pair of primers following the standard protocol with the BioRad CFX 96 real-time system ( 26 , 27 , 29 ). For amplification with the Bio-Rad system, following protocol was used: 95 C for 30 s, 39 cycles at 95°C for 30 s (denaturation), 59°C for 30 s (annealing), and 72°C for 1 min (extension) including the plate read.…”

Section: Methodsmentioning

confidence: 99%

“…Notably, MSP-ZEWBs showed negligible nonspecific adsorptions of proteins ( 25 ), indicating that the adsorption of plasma cfDNA with MSP-ZEWBs at a pH of approximately 4.0 may need no protein denaturation and be resistant to cells remaining in plasma. For comparison of plasma cfDNA yields based on the quantification of a DNA sequence in plasma cfDNA via quantitative polymerase-chain-reaction (qPCR), a coding fragment in an exon of the Alu gene found in common blood cells is a favorable model to examined the interference of remaining blood cells in plasmas ( 26 , 27 ). In our study, qPCR of a coding fragment of the Alu gene revealed that the extraction of plasma cfDNA with MSP-ZEWBs required no denaturation of proteins, prevented cells from remaining in the plasma, and was sufficiently absorbed to promote liquid biopsy of cancers.…”

Section: Introductionmentioning

confidence: 99%

Ampholytic ion-exchange magnetic beads: a promising tool for selecting short fragments in circulating cell-free DNA analysis

He,

Wang,

Zhou

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveFor liquid biopsy of cancer, the extraction of circulating cell-free DNA (cfDNA) from plasma is required. We evaluated the efficacy of use of magnetic submicron particles coated with abundant small zwitterions (MSP-ZEWBs) for extracting short fragments of cfDNA.MethodsWe developed and optimized an MSP-ZEWB-based cfDNA extraction method using ampholytic ion-exchange materials and compared its results with those using a control kit. We measured the cfDNA concentration by quantitative polymerase-chain-reaction and using the Qubit method and analyzed cfDNA fragmentation patterns using a bioanalyzer.ResultsThe fragment size of cfDNA isolated from glycine hydrochloric acid at a pH of 2.2 exhibited a better alignment with the DNA marker. The highest DNA intensity was observed at the final concentration of 0.8% polyethylene glycol 8000. The intensity of cfDNA decreased significantly when isolated from plasma with DNA marker using MSP-ZEWBs with an adsorption buffer containing guanidine hydrochloride or isothiocyanoguanidine. All fragments were successfully extracted using MSP-ZEWBs from both plasma and phosphate-buffered saline. Notably, the intensity of short cfDNA fragments isolated using MSP-ZEWBs remained consistent for recovery of long DNA fragments. indicating a potential selective of small fragments.ConclusionThe extraction of plasma cfDNA with MSP-ZEWBs requires no protein denaturation, shows resistance to cells remaining in plasma, and demonstrates higher overall efficiency and better reproducibility than other extraction methods. Use of MSP-ZEWBs may greatly enhance liquid biopsy of cancers through the analysis of plasma cfDNA in clinical practice.

show abstract

“…There are approximately 3.76 million new cases and 1.91 million death cases of CRC in the Chinese population (4,5). The pathogenesis of CRC involves both genetic and environmental factors (6,7). Although the screening strategies have advanced in recent years, there are still many CRC patients who are diagnosed in the advanced stage due to untimely screening and obscure symptoms 7 .…”

Section: Introductionmentioning

confidence: 99%

“…The pathogenesis of CRC involves both genetic and environmental factors (6,7). Although the screening strategies have advanced in recent years, there are still many CRC patients who are diagnosed in the advanced stage due to untimely screening and obscure symptoms 7 . Therefore, it is extremely important to clarify the pathogenesis of CRC to search for diagnostic and therapeutic targets (8,9).…”

Section: Introductionmentioning

confidence: 99%

LINC00339 accelerates invasion and migration of colorectal cancer via mediating miRNA-30a-5p

Peng Zhou,

Jie Wu,

Zihan Zheng

et al. 2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Circulating cell-free-DNA concentration is a good biomarker for diagnosis of colorectal cancer in Mexican patients

Cited by 10 publications

References 40 publications

Exploring the Role of Circulating Cell-Free DNA in Disease Diagnosis and Therapy

Exploring the Role of Circulating Cell-Free DNA in Disease Diagnosis and Therapy

Ampholytic ion-exchange magnetic beads: a promising tool for selecting short fragments in circulating cell-free DNA analysis

LINC00339 accelerates invasion and migration of colorectal cancer via mediating miRNA-30a-5p

Contact Info

Product

Resources

About